Immune checkpoint inhibitor-based regimens have been established as the standard-of-care first-line treatment in the setting of metastatic NSCLC. However, novel combination approaches are called for to further improve outcomes.
Improving long-term survival remains an unmet need in the setting of extensive-stage small-cell lung cancer (ES-SCLC). This might be attributed at least in part to the complexity of the tumor microenvironment, which is characterized by immunosuppression, angiogenesis and vascularization.
In the first-line setting of EGFR-mutant advanced NSCLC, EGFR tyrosine kinase inhibitors (TKIs) such as the third-generation agent osimertinib have been established as the standard of care, although treatment is followed by disease progression in most patients. Data on the combined administration of EGFR TKIs with chemotherapy suggest enhanced efficacy.
Given the high incidence and mortality rates of lung cancer in Taiwan and the established association between survival and disease stage at diagnosis, the Taiwanese national early detection program for lung cancer was launched in July 2022 with the aim of increasing the proportion of tumors identified at an early stage using low-dose CT (LDCT).
The International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) was held in Singapore and virtually from 9th to 12th September. This prestigious event served as a global gathering point uniting over 6,000 renowned international scientists, researchers, and devoted patient advocates.
ASCO 2023 Lung Cancer - Marjorie Zauderer Marjorie G. ...
ASCO 2023 Lung Cancer - John Heymach John Heymach prov ...
Considering the need for new, well tolerated and effective treatments to improve survival in metastatic NSCLC after platinum-based chemotherapy, Tumor Treating Fields (TTFields) therapy represents an innovative option. TTFields are electric fields that exert physical forces on electrically charged cellular components in dividing cancer cells, thus disrupting cell function.
cquired resistance to EGFR tyrosine kinase inhibitors (TKIs), even including the third-generation agent osimertinib, limits duration of response and survival in treated patients with EGFR-mutant lung tumors. A potential strategy to improve outcomes is the concomitant use of EGFR-targeted agents and platinum doublet chemotherapy, although EGFR TKI treatment might attenuate the effect of cytotoxic agents.
As is known, patients with extensive-stage small-cell lung cancer (ES-SCLC) tend to respond well to systemic induction therapy but frequently experience rapid disease progression. Subsequent treatment success remains a challenge; therefore, improving outcomes in the first line appears critical. Poly (ADP-ribose) polymerase (PARP) 1 has emerged as a potential therapeutic target in neuroendocrine tumors such as SCLC.
